First Time Loading...

Sartorius Stedim Biotech SA
PAR:DIM

Watchlist Manager
Sartorius Stedim Biotech SA Logo
Sartorius Stedim Biotech SA
PAR:DIM
Watchlist
Price: 173.85 EUR 5.84% Market Closed
Updated: Jul 27, 2024
Have any thoughts about
Sartorius Stedim Biotech SA?
Write Note
Section:
 
🌟 We're looking for content creator

Wall Street
Price Targets

DIM Price Targets Summary
Sartorius Stedim Biotech SA

Wall Street analysts forecast DIM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DIM is 253.61 EUR with a low forecast of 181.8 EUR and a high forecast of 378 EUR.

DIM Lowest Forecast
Wall Street Target
181.8 EUR
5% Upside
DIM Average Forecast
Wall Street Target
253.61 EUR
46% Upside
DIM Highest Forecast
Wall Street Target
378 EUR
117% Upside
Lowest
Price Target
181.8 EUR
5% Upside
Average
Price Target
253.61 EUR
46% Upside
Highest
Price Target
378 EUR
117% Upside
Sartorius Stedim Biotech SA Competitors:
Price Targets
QGEN
Qiagen NV
16% Upside
DHR
Danaher Corp
1% Upside
ONT
Oxford Nanopore Technologies PLC
53% Upside
NEO
Neogenomics Inc
37% Upside
QGEN
Qiagen NV
16% Upside
DHR
Danaher Corp
1% Upside
ONT
Oxford Nanopore Technologies PLC
53% Upside
NEO
Neogenomics Inc
37% Upside
ABSI
Absci Corp
82% Upside
G
GENO
Genovis AB
79% Upside
688222
HitGen Inc
67% Upside
AZTA
Azenta Inc
1% Upside

Revenue
Forecast

Revenue Estimate
Sartorius Stedim Biotech SA

For the last 8 years the compound annual growth rate for Sartorius Stedim Biotech SA's revenue is 15%. The projected CAGR for the next 3 years is 11%.

15%
Past Growth
11%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Sartorius Stedim Biotech SA

For the last 8 years the compound annual growth rate for Sartorius Stedim Biotech SA's operating income is 11%. The projected CAGR for the next 3 years is 27%.

11%
Past Growth
27%
Estimated Growth
Estimates Accuracy
0%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Sartorius Stedim Biotech SA

For the last 8 years the compound annual growth rate for Sartorius Stedim Biotech SA's net income is 13%. The projected CAGR for the next 3 years is 31%.

13%
Past Growth
31%
Estimated Growth
Estimates Accuracy
-15%
Average Miss
What are analyst estimates?

See Also

Summary
DIM intrinsic value, competitors valuation, and company profile.
DCF Valuation
DIM stock valuation using Discount Cash Flow valuation method.
Relative Valuation
DIM stock valuation using valuation multiples.
Wall Street Estimates
DIM price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
DIM stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is DIM's stock price target?
Price Target
253.61 EUR

According to Wall Street analysts, the average 1-year price target for DIM is 253.61 EUR with a low forecast of 181.8 EUR and a high forecast of 378 EUR.

What is Sartorius Stedim Biotech SA's Revenue forecast?
Projected CAGR
11%

For the last 8 years the compound annual growth rate for Sartorius Stedim Biotech SA's revenue is 15%. The projected CAGR for the next 3 years is 11%.

What is Sartorius Stedim Biotech SA's Operating Income forecast?
Projected CAGR
27%

For the last 8 years the compound annual growth rate for Sartorius Stedim Biotech SA's operating income is 11%. The projected CAGR for the next 3 years is 27%.

What is Sartorius Stedim Biotech SA's Net Income forecast?
Projected CAGR
31%

For the last 8 years the compound annual growth rate for Sartorius Stedim Biotech SA's net income is 13%. The projected CAGR for the next 3 years is 31%.

ALPHA SPREAD
Join more than 160,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.